๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Antimitochondrial antibodies in acute liver failure: Implications for primary biliary cirrhosis

โœ Scribed by Patrick S. C. Leung; Lorenzo Rossaro; Paul A. Davis; Ogyi Park; Atsushi Tanaka; Kentaro Kikuchi; Hiroshi Miyakawa; Gary L. Norman; William Lee; M. Eric Gershwin


Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
195 KB
Volume
46
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

โœฆ Synopsis


In our previous work, including analysis of more than 10,000 sera from control patients and patients with a variety of liver diseases, we have demonstrated that with the use of recombinant autoantigens, antimitochondrial autoantibodies (AMAs) are only found in primary biliary cirrhosis (PBC) and that a positive AMA is virtually pathognomonic of either PBC or future development of PBC. Although the mechanisms leading to the generation of AMA are enigmatic, we have postulated that xenobiotic-induced and/or oxidative modification of mitochondrial autoantigens is a critical step leading to loss of tolerance. This thesis suggests that a severe liver oxidant injury would lead to AMA production. We analyzed 217 serum samples from 69 patients with acute liver failure (ALF) collected up to 24 months post-ALF, compared with controls, for titer and reactivity with the E2 subunits of pyruvate dehydrogenase, branched chain 2-oxo-acid dehydrogenase, and 2-oxo-glutarate dehydrogenase. AMAs were detected in 28/69 (40.6%) ALF patients with reactivity found against all of the major mitochondrial autoantigens. In addition, and as further controls, sera were analyzed for autoantibodies to gp210, Sp100, centromere, chromatin, soluble liver antigen, tissue transglutaminase, and deaminated gliadin peptides; the most frequently detected nonmitochondrial autoantibody was against tissue transglutaminase (57.1% of ALF patients).

Conclusion:

The strikingly high frequency of amas in alf supports the thesis that oxidative stress-induced liver damage may lead to ama induction. the rapid disappearance of amas in these patients provides further support for the contention that pbc pathogenesis requires additional factors, including genetic susceptibility.


๐Ÿ“œ SIMILAR VOLUMES


Caspase induction by IgA antimitochondri
โœ Shuji Matsumura; Judy Van de Water; Patrick Leung; Joseph A. Odin; Kazuhide Yama ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 165 KB ๐Ÿ‘ 1 views

## Anti -mitochondrial antibodies (AMAs) have long been recognized as a serological hallmark of primary biliary cirrhosis (PBC). Although high titers of immunoglobulin (Ig)A AMAs are found in bile, saliva, and urine of patients, a pathogenic role for this antibody has remained elusive. Functional

A sensitive bead assay for antimitochond
โœ Sabine Oertelt; Roman Rieger; Carlo Selmi; Pietro Invernizzi; Aftab A. Ansari; R ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 288 KB ๐Ÿ‘ 1 views

The antimitochondrial response in primary biliary cirrhosis (PBC) is the most highly directed and specific self-reacting antibody in human immunopathology. Originally, antimitochondrial antibodies (AMAs) were detected by indirect immunofluorescence (IIF) and found in approximately 90% of well-docume

Increased prevalence of antimitochondria
โœ Konstantinos N. Lazaridis; Brian D. Juran; Gwen M. Boe; Joshua P. Slusser; Mariz ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 187 KB ๐Ÿ‘ 1 views

Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disorder that can progress to cirrhosis, shortening life expectancy. PBC patients are often asymptomatic, present with biochemical cholestasis, and test positive (>90%) for antimitochondrial antibodies (AMAs) in serum. Although AMA posit

Does antimitochondrial antibody status a
โœ W R Kim; J J Poterucha; R A Jorgensen; K P Batts; H A Homburger; E R Dickson; R ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 270 KB ๐Ÿ‘ 1 views

rum. 1 In the past decade, two treatment modalities have Approximately 5% to 10% of patients with features otherbeen shown to be effective in the treatment for PBC, dewise consistent with primary biliary cirrhosis (PBC) lack antipending on the stage of the disease. For patients with less mitochondri